X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IMG-007 is a humanized anti-OX40 IgG1 mAb, with a silenced ADCC function and an extended half-life. It is designed to target immunological diseases like atopic dermatitis.
Lead Product(s): IMG-007
Therapeutic Area: Dermatology Product Name: IMG-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2024
Details:
Inmagene has exercised options to license two drug candidates discovered by HUTCHMED, IMG-007, an investigational OX40 antagonistic monoclonal antibody and IMG-004, a reversible, non-covalent, highly selective oral BTK inhibitor designed to target immunological diseases.
Lead Product(s): IMG-007
Therapeutic Area: Dermatology Product Name: IMG-007
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Hutchmed
Deal Size: $455.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 02, 2024
Details:
IMG-007 is a humanized IgG1 mAb that specifically binds to the OX40 receptor and potently blocks the signaling between OX40 and its ligand, being evaluated for the treatment of alopecia areata (AA) and atopic dermatitis (AD).
Lead Product(s): IMG-007
Therapeutic Area: Dermatology Product Name: IMG-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2023
Details:
IMG-007 is a humanized IgG1 mAb that specially binds to the OX40 receptor with high affinity and is being investigated for the treatment of moderate-to-severe atopic dermatitis.
Lead Product(s): IMG-007
Therapeutic Area: Dermatology Product Name: IMG-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2023
Details:
IMG-007 is a humanized IgG1 monoclonal antibody that specifically binds to the OX40 receptor, which is investigated for the adult patients with moderate-to-severe atopic dermatitis.
Lead Product(s): IMG-007
Therapeutic Area: Dermatology Product Name: IMG-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2023
Details:
IMG-004 is a potent, non-covalent, reversible, and brain permeable third-generation Bruton's tyrosine kinase (BTK) inhibitor. It is being developed as a potential treat immunological diseases.
Lead Product(s): IMG-004
Therapeutic Area: Neurology Product Name: IMG-004
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hutchmed
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2023
Details:
IMG-008 is a novel long-acting antagonistic monoclonal antibody having high binding affinity to IL-36R and has potent in vitro activity to block IL-36R downstream signaling and cytokine release. It is being developed to potentially treat auto-inflammatory diseases.
Lead Product(s): IMG-008
Therapeutic Area: Immunology Product Name: IMG-008
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2023
Details:
IMG-004 is a non-covalent, reversible small molecule inhibitor targeting BTK. Designed specifically for inflammatory and autoimmune diseases that usually require long-term treatment, IMG-004 is potent, highly selective and brain permeable.
Lead Product(s): IMG-004
Therapeutic Area: Neurology Product Name: IMG-004
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hutchmed
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2022
Details:
IMG-007 is a novel antagonistic monoclonal antibody targeting the OX40 receptor, blocks the OX40 activity and has demonstrated high potency in preclinical studies, indicating a best-in-class potential.
Lead Product(s): IMG-007
Therapeutic Area: Dermatology Product Name: IMG-007
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Hutchmed
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2022
Details:
IMG-004 is a non-covalent, reversible small molecule inhibitor targeting Bruton's tyrosine kinase (BTK). Designed specifically for inflammatory and autoimmune diseases that usually require long-term treatment.
Lead Product(s): IMG-004
Therapeutic Area: Neurology Product Name: IMG-004
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hutchmed
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
